Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer

S. DEL CARMEN; F. CHAIN; J.G. LEBLANC; S. DEL CARMEN; F. CHAIN; J.G. LEBLANC; M. LENOIR; D. MUÑOZ-PROVENCIO; A. DE MORENO DE LEBLANC; M. LENOIR; D. MUÑOZ-PROVENCIO; A. DE MORENO DE LEBLANC; N.G. CORTES-PEREZ; P. LANGELLA; L. BERMUDEZ-HUMARAN; N.G. CORTES-PEREZ; P. LANGELLA; L. BERMUDEZ-HUMARAN

JOURNAL OF GASTROENTEROLOGY

SPRINGER TOKYO

Lugar: Tokyo; Año: 2016 vol. 51 p. 862 - 873

0944-1174

Chronic intestinal inflammation alters host physiology and could lead to colorectal cancer (CRC). Many studies have shown the efficiency of probiotics in the prevention and/or treatment of Inflammatory Bowel Diseases (IBD). We have reported previously the beneficial effects of Lactobacillus casei BL23 in different murine models of intestinal inflammation. Moreover, there is emerging on the potential beneficial effects of probiotics in CRC. Here we thus explored the effects of L. casei BL23 on CRC and also on another non-intestinal cancer model. Our results show that oral treatment with this probiotic anti-inflammatory bacterium modulates host immune responses, significantly reduced the tumour volume in the HPV-tumor model and protected mice against 1,2-dimethylhydrazine (DMH)-induced CRC. Indeed, L. casei BL23-treated splenocytes showed significantly higher levels of Th17 and lower levels of Treg T-cell percentages than PBS-treated control cells. However, at the intestinal level, an anti-inflammatory response with increased IL-10 and decreased recruitment of macrophages accompanied the anti-tumor effect in probiotic administered mice. These results confirm the host immunomodulatory properties of L. casei BL23 that can exert benefices against tumors not only at the intestinal level but also systemically.